162 related articles for article (PubMed ID: 7482406)
21. Sulfatide-dependent autoactivation of human blood coagulation Factor XII (Hageman Factor).
Tans G; Rosing J; Griffin JH
J Biol Chem; 1983 Jul; 258(13):8215-22. PubMed ID: 6553053
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin.
Rauch J; Tannenbaum M; Neville C; Fortin PR
Thromb Haemost; 1998 Dec; 80(6):936-41. PubMed ID: 9869164
[TBL] [Abstract][Full Text] [Related]
23. Immunization of a rabbit with beta 2-glycoprotein I induces charge-dependent crossreactive antibodies that bind anionic phospholipids and have similar reactivity as autoimmune anti-phospholipid antibodies.
Kouts S; Wang MX; Adelstein S; Krilis SA
J Immunol; 1995 Jul; 155(2):958-66. PubMed ID: 7608571
[TBL] [Abstract][Full Text] [Related]
24. Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor.
Salemink I; Blezer R; Willems GM; Galli M; Bevers E; Lindhout T
Thromb Haemost; 2000 Oct; 84(4):653-6. PubMed ID: 11057865
[TBL] [Abstract][Full Text] [Related]
25. Lupus anticoagulant in cardiovascular diseases: the role of beta2-glycoprotein I.
de Groot PG; Bouma B; Lutters BC; Derksen RH
Ann Med; 2000 Dec; 32 Suppl 1():32-6. PubMed ID: 11209979
[TBL] [Abstract][Full Text] [Related]
26. Beta2-glycoprotein I, anti-beta2-glycoprotein I, and fibrinolysis.
Yasuda S; Atsumi T; Ieko M; Koike T
Thromb Res; 2004; 114(5-6):461-5. PubMed ID: 15507279
[TBL] [Abstract][Full Text] [Related]
27. Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome.
Hanly JG; Smith SA
J Rheumatol; 2000 Sep; 27(9):2152-9. PubMed ID: 10990227
[TBL] [Abstract][Full Text] [Related]
28. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies.
Del Papa N; Sheng YH; Raschi E; Kandiah DA; Tincani A; Khamashta MA; Atsumi T; Hughes GR; Ichikawa K; Koike T; Balestrieri G; Krilis SA; Meroni PL
J Immunol; 1998 Jun; 160(11):5572-8. PubMed ID: 9605162
[TBL] [Abstract][Full Text] [Related]
29. Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I.
Shi T; Iverson GM; Qi JC; Cockerill KA; Linnik MD; Konecny P; Krilis SA
Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3939-44. PubMed ID: 15007174
[TBL] [Abstract][Full Text] [Related]
30. Anticardiolipin and anti-beta-2-glycoprotein I antibodies.
Marai I; Tincani A; Balestrieri G; Shoenfeld Y
Autoimmunity; 2005 Feb; 38(1):33-8. PubMed ID: 15804703
[TBL] [Abstract][Full Text] [Related]
31. Anti-phospholipid antibodies in the mercuric chloride treated brown Norway rat.
Marriott JB; Qasim F; Oliveira DB
J Autoimmun; 1994 Aug; 7(4):457-67. PubMed ID: 7980848
[TBL] [Abstract][Full Text] [Related]
32. beta 2-Glycoprotein I and anti-beta 2-glycoprotein I antibodies: where are we now?
Inanç M; Radway-Bright EL; Isenberg DA
Br J Rheumatol; 1997 Dec; 36(12):1247-57. PubMed ID: 9448584
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic methodologies for circulating anticoagulants.
Exner T
Thromb Haemost; 1995 Jul; 74(1):338-44. PubMed ID: 8578481
[TBL] [Abstract][Full Text] [Related]
34. Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus.
Szodoray P; Tarr T; Tumpek J; Kappelmayer J; Lakos G; Poor G; Szegedi G; Kiss E
Autoimmunity; 2009 Sep; 42(6):497-506. PubMed ID: 19626489
[TBL] [Abstract][Full Text] [Related]
35. Anti-idiotypic antibodies against anti-phospholipid autoantibodies which suppress lupus-like anticoagulant activity.
Gris JC; Schved JF; Tousch D; Hereil S; Feugeas O
Nouv Rev Fr Hematol (1978); 1988; 30(3):143-7. PubMed ID: 3138656
[TBL] [Abstract][Full Text] [Related]
36. Binding and activation properties of human factor XII, prekallikrein, and derived peptides with acidic lipid vesicles.
Griep MA; Fujikawa K; Nelsestuen GL
Biochemistry; 1985 Jul; 24(15):4124-30. PubMed ID: 3876845
[TBL] [Abstract][Full Text] [Related]
37. [Antiphospholipid antibodies: clinical significance and biological diagnosis].
Arnoux D; Boutière B; Sanmarco M
Ann Biol Clin (Paris); 2000; 58(5):557-74. PubMed ID: 11022099
[TBL] [Abstract][Full Text] [Related]
38. Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII--an immunochemical and homology modeling approach.
Citarella F; te Velthuis H; Helmer-Citterich M; Hack CE
Thromb Haemost; 2000 Dec; 84(6):1057-65. PubMed ID: 11154114
[TBL] [Abstract][Full Text] [Related]
39. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids.
Rauch J; Tannenbaum M; Janoff AS
Thromb Haemost; 1989 Nov; 62(3):892-6. PubMed ID: 2512678
[TBL] [Abstract][Full Text] [Related]
40. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
